Pharma Equity Group A/S (PEG.CO)

DKK 0.18

(-2.17%)

EBITDA Summary of Pharma Equity Group A/S

  • Pharma Equity Group A/S's latest annual EBITDA in 2023 was -24.79 Million DKK , down -1771.27% from previous year.
  • Pharma Equity Group A/S's latest quarterly EBITDA in 2024 Q2 was -4.86 Million DKK , up 27.45% from previous quarter.
  • Pharma Equity Group A/S reported an annual EBITDA of 4.47 Million DKK in 2022, down -209.77% from previous year.
  • Pharma Equity Group A/S reported an annual EBITDA of 6.05 Million DKK in 2021, up 106.44% from previous year.
  • Pharma Equity Group A/S reported a quarterly EBITDA of -4.86 Million DKK for 2024 Q2, up 27.45% from previous quarter.
  • Pharma Equity Group A/S reported a quarterly EBITDA of -13.11 Million DKK for 2023 Q4, down -233.05% from previous quarter.

Annual EBITDA Chart of Pharma Equity Group A/S (2023 - 2008)

Historical Annual EBITDA of Pharma Equity Group A/S (2023 - 2008)

Year EBITDA EBITDA Growth
2023 -24.79 Million DKK -1771.27%
2022 4.47 Million DKK -209.77%
2021 6.05 Million DKK 106.44%
2020 -32.6 Million DKK -1022.62%
2019 -14.38 Million DKK -186.13%
2018 -7.58 Million DKK -19.33%
2017 177 Thousand DKK 473.45%
2016 -2.01 Million DKK 75.49%
2015 -2.62 Million DKK -38.41%
2014 -5.99 Million DKK -184.21%
2013 -135.32 Million DKK 147.45%
2012 -4.75 Million DKK -418.36%
2011 1.49 Million DKK -55.91%
2010 3.38 Million DKK 466.23%
2009 -924 Thousand DKK 99.0%
2008 -92.66 Million DKK 0.0%

Peer EBITDA Comparison of Pharma Equity Group A/S

Name EBITDA EBITDA Difference
ALK-Abelló A/S 913 Million DKK 102.716%
Bavarian Nordic A/S 2.05 Billion DKK 101.209%
Genmab A/S 5.56 Billion DKK 100.446%
Gubra A/S -28.89 Million DKK 14.175%
Novo Nordisk A/S 113.33 Billion DKK 100.022%
Orphazyme A/S -26.04 Million DKK 4.795%
Zealand Pharma A/S -651.58 Million DKK 96.194%